Real-life data on Selexipag for the treatment of pulmonary hypertension

Michaela Barnikel,Nikolaus Kneidinger,Friederike Klenner,Andrea Waelde,P. Arnold,Torben Sonneck,Jürgen Behr,Claus Neurohr,Katrin Milger

Real-life data on Selexipag for the treatment of pulmonary hypertension

2019

Michaela Barnikel
Nikolaus Kneidinger
Friederike Klenner
Andrea Waelde
P. Arnold
Torben Sonneck
Jürgen Behr
Claus Neurohr
Katrin Milger

Selexipag is an orally available selective IP prostacyclin-receptor agonist licensed since 2016 for the therapy of pulmonary arterial hypertension (PAH). We aimed to describe real-life data of pati...

Keywords:

Pulmonary hypertension
Cardiology
Selexipag
Medicine
Internal medicine
Hemodynamics
Risk assessment
Gastroenterology
Cohort
Tolerability
real life data
Side effect

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations